LENZ Therapeutics

While the FDA is facing a disrupted and uncharted future, drug development offers a few certainties, including that oncology and neuroscience still dominate the novel agents seeking approval. But the

LENZ Therapeutics has picked out the eye drop LNZ100 as its lead candidate for presbyopia and is confident it has a large potential commercial market, with new Phase III data showing rapid improvemen

After what seemed like a relatively quiet stretch for venture capital mega-rounds of $100m or more, the pace of large VC financings has picked up in March with five big rounds announced already this m

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Juniper Acquires Kolon’s Cell-Mediated